301 related articles for article (PubMed ID: 19710593)
41. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
42. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
[TBL] [Abstract][Full Text] [Related]
43. Etravirine: R165335, TMC 125, TMC-125, TMC125.
Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
[TBL] [Abstract][Full Text] [Related]
44. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.
Girard PM; Campbell TB; Grinsztejn B; Hartikainen J; Rachline A; Nijs S; Witek J
HIV Med; 2012 Aug; 13(7):427-35. PubMed ID: 22413938
[TBL] [Abstract][Full Text] [Related]
45. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
[TBL] [Abstract][Full Text] [Related]
46. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.
Grennan T; Walmsley S
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(6):354-63. PubMed ID: 19855100
[TBL] [Abstract][Full Text] [Related]
47. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
DeJesus E; Fätkenheuer G; Orrell C; Wang C; Jones J; Craig C; Tawadrous M; Heera J
HIV Clin Trials; 2014; 15(5):209-17. PubMed ID: 25350959
[TBL] [Abstract][Full Text] [Related]
49. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
[TBL] [Abstract][Full Text] [Related]
50. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
[TBL] [Abstract][Full Text] [Related]
51. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.
Cella D; Gilet H; Viala-Danten M; Peeters K; Dubois D; Martin S
HIV Clin Trials; 2010; 11(1):18-27. PubMed ID: 20400408
[TBL] [Abstract][Full Text] [Related]
52. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
53. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Antivir Ther; 2010; 15(6):817-29. PubMed ID: 20834094
[TBL] [Abstract][Full Text] [Related]
54. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
55. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S; Galli L; Visco F; Soria A; Canducci F; Salpietro S; Gianotti N; Bigoloni A; Torre LD; Tambussi G; Lazzarin A; Castagna A
AIDS; 2010 Mar; 24(6):924-8. PubMed ID: 20154578
[TBL] [Abstract][Full Text] [Related]
56. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
[TBL] [Abstract][Full Text] [Related]
58. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N; Cahn P; Molina JM; Mills A; Nijs S; Vingerhoets J; Witek J
Int J STD AIDS; 2010 Nov; 21(11):738-40. PubMed ID: 21187353
[TBL] [Abstract][Full Text] [Related]
59. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients.
Calcagno A; Marinaro L; Nozza S; Aldieri C; Carbone A; Ghisetti V; Trentalange A; D'Avolio A; Castagna A; Di Perri G; Bonora S
Antiviral Res; 2014 Aug; 108():44-7. PubMed ID: 24861522
[TBL] [Abstract][Full Text] [Related]
60. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Arathoon E; Bhorat A; Silaghi R; Crauwels H; Lavreys L; Tambuyzer L; Van Baelen B; Vanveggel S; Opsomer M
SAGE Open Med; 2017; 5():2050312116686482. PubMed ID: 28382208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]